Tel: +7 495 937 43 18
info@almedis.ru
Ru
Eng
News
News
Q3 2023
  • In a phase I oncological trial recruitment to a double-dose cohort has been completed.
  • Almedis General manager participated in ECRC-EAFO (Eurasian Cancer Research Council, Eurasian Federation of Oncology) Seminar on Academic Clinical Research in Oncology and Hematology, in Moscow, spoke about the regulatory aspects of clinical trials.

Q2 2023

  • 70% of patients were enrolled and the scheduled interim analysis was performed in the oncology study (breast cancer).
  • In a phase I oncological trial interim analysis was performed and recruitment to a multiple-dose cohort started.
Q1 2023
  • Database was closed, statistical analysis was performed and study report was prepared in the RWD study in transplantology.
  • Study report was prepared in the hematology study (hemophilia).
  • Patients recruitment is ongoing in a phase I oncological trial.
Q4 2022
  • A meeting of the scientific advisory committee was held in a phase I oncological trial to assess the results of using the drug in the first dose cohort of patients. A decision was made to continue enrollment in the study.
  • 50% of patients were enrolled and the scheduled interim analysis was performed in the oncology study (breast cancer).
  • Interim analysis was performed in infection diseases project (HCV plus HIV).
  • The collection of information in the RWD study in transplantology started.
Q3 2022
  • A meeting of the scientific advisory committee was held in a phase I oncological trial to assess the results of using the drug in the first patient. A decision was made to continue enrollment in the study.
  • Almedis prepared information and materials for the publication of the results for the study of real world data with forecasting trends in oncology.
  • Almedis prepared information and materials for the publication of the results for the study of the prevalence of oncogenic viral infections among patients at various clinics.
  • Data collection completed and all sites have been closed in the hematology study (hemophilia).
  • An interim analysis was performed and, based on its results, an annual investigators’ meeting was held in the oncology study (breast cancer).
Q2 2022
In the current challenging satiation at local clinical trials market, Almedis strictly fulfills its obligations in ongoing projects.

  • Almedis representative, as part of an ACTO delegation, visited Kazakhstan to assess the current state and potential of the clinical trials market in this country.
  • In a phase I oncology trial, all centers are initiated, and the first patient has received an investigational product.
  • The previously suspended enrollment of patients in a non-interventional study in oncohematology has been resumed.
Q1 2022
  • Starting from the end of February 2022, Almedis makes every effort to ensure the rights and well-being of patients participating in ongoing trials and takes part in the work of ACTO to monitor the situation and find optimal solutions to support clinical trials in Russia.
  • A notice of completion in Russia of an international phase 4 IIT comparing different regimens of antithrombotic therapy in pregnant women has been submitted to the Ministry of Health of the Russian Federation.
  • The study of comorbidities in patients with chronic viral infection was completed.
  • The study to evaluate antibiotic use in children with vaccine-controlled viral infections has started.
  • The study to evaluate HIV drug resistance in Russia has started.
Q3-Q4 2021
  • The study of glycemic control in patients with diabetes mellitus completed, database has been closed.
  • The study of real data with forecasting trends in oncology has completed.
  • The study of the prevalence of oncogenic viral infections among patients at various clinics has completed, database has been closed.
  • Patient recruitment completed and data for interim analysis has been prepared in a hemophilia study.
  • The study of comorbidities in patients with chronic viral infection has started.
  • Phase 1 oncology study has started.
  • Results of previously completed study in neurology (treatment of non-specific low back pain) has been published at clinicaltrials.gov.
Q2 2021
  • ALMEDIS took part in the educational program of the Russian Society of Clinical Oncology (RUSSCO) for young scientists, holding a webinar "Research planning and problem setting"
  • The study in oncohematology (multiple myeloma) has started
  • The study in oncology (breast cancer) has started
  • BE study was carried out
Q1 2021
  • The study in neurology (treatment of non-specific low back pain) has been completed
  • The study of real world data with forecasting trends in oncology has started
  • The study of the prevalence of oncogenic viral infections among patients at various clinics has started
  • The study of intestinal microflora in newborns has been completed